Loading...
•
Jun 30
Allogene Q2 2025 Earnings Report
Allogene Therapeutics reported its second quarter 2025 financial results and provided business updates, highlighting progress in its clinical trials and a strong cash position.
Key Takeaways
Allogene Therapeutics reported a net loss of $50.9 million for Q2 2025, or $0.23 per share, an improvement from the previous year. The company ended the quarter with $302.6 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027. Key clinical trials, including ALPHA3 for LBCL and RESOLUTION for autoimmune disease, are progressing, with significant milestones expected in 1H 2026.
Net loss for Q2 2025 was $50.9 million, or $0.23 per share, showing an improvement compared to the prior year.
The company maintained a strong financial position, ending Q2 2025 with $302.6 million in cash, cash equivalents, and investments.
Allogene projects its cash runway to extend into the second half of 2027, indicating financial stability for ongoing operations.
Significant progress was made in clinical trials, with the ALPHA3 trial proceeding as a two-arm randomized study and the RESOLUTION basket trial in rheumatology initiated.
Allogene
Allogene
Forward Guidance
Allogene Therapeutics expects its cash runway to extend into the second half of 2027. The company anticipates a decrease in cash, cash equivalents, and investments of approximately $150 million for 2025, with GAAP Operating Expenses projected to be around $230 million, including approximately $45 million in non-cash stock-based compensation expense. These estimates exclude any impact from potential business development activities.
Positive Outlook
- Cash runway projected into the second half of 2027, providing long-term financial stability.
- Futility analysis for the ALPHA3 trial expected in 1H 2026, a key milestone for cema-cel.
- First clinical update for ALLO-329 in autoimmune disease expected in 1H 2026, including biomarker and proof-of-concept data.
- Alignment with FDA on pivotal trial design for ALLO-316, supporting potential partnership discussions.
- Expansion of ALPHA3 trial with over 50 activated sites across the U.S. and Canada, with international expansion underway.
Challenges Ahead
- Expected decrease in cash, cash equivalents, and investments of approximately $150 million for 2025.
- GAAP Operating Expenses are expected to be approximately $230 million for 2025, indicating significant ongoing costs.
- Estimates exclude any impact from potential business development activities, which could alter financial projections.
- The company's product candidates are based on novel technologies, making it difficult to predict development time and cost.
- Potential for undesirable side effects or other properties of product candidates that could halt clinical development or limit commercial potential.